Dr. Reddy's Laboratories Ltd. (DRREDDY): Dr. Reddy's Laboratories Share Price rises 2.73% to Rs 1,204

Published: 18 September 2026 at 9:49:48 AM IST

Dr. Reddy's Laboratories Share Price rose to Rs 1,204, up 2.73% today, with the company carrying a market capitalisation of Rs 95,591.76 crore. The move took the stock above its previous close of Rs 1,172.05 after opening at Rs 1,184.80 and touching an intraday high of Rs 1,204.25.

The available data confirms the price event, but it does not establish a company-specific catalyst. In Univest coverage terms, this makes the session relevant as a verified share price rise, a turnover-led trading update and a fresh comparison point for Dr. Reddy's Laboratories Share Price Today. The latest stock news also matters because the company sits in the Healthcare sector and Pharmaceuticals & Drugs industry, where valuation and profitability are often read alongside price action. Investors tracking Dr. Reddy's Laboratories Share Price can monitor the next session for follow-through in price, turnover and any newly disclosed business updates.

Dr. Reddy's Laboratories Share Price Today: Price Action Analysis

Metric	Value
Current Price	Rs 1,204
Previous Close	Rs 1,172.05
Today's Move	Rs 31.95 (+2.73%)
Open	Rs 1,184.8
High	Rs 1,204.25
Low	Rs 1,172.05
Turnover	Rs 4.12 crore
Market Capitalisation	Rs 95,591.76 crore
Market Cap Category	Large Cap

Dr. Reddy's Laboratories Ltd. (DRREDDY) rose to Rs 1,204 from the previous close of Rs 1,172.05, a move of Rs 31.95 or 2.73%. The stock opened at Rs 1,184.8, reached a high of Rs 1,204.25, recorded a low of Rs 1,172.05.

Dr. Reddy's Laboratories Share Price Today reflected a clear same-day gain of Rs 31.95, or 2.73%, from the previous close of Rs 1,172.05 to Rs 1,204. The day’s low matched the previous close at Rs 1,172.05, while the stock reached an intraday high of Rs 1,204.25, which was just above the closing level. Turnover stood at Rs 4.12 crore, giving a factual snapshot of the day’s traded value. The stock therefore finished near the top end of its daily range, and the move places Dr. Reddy's Laboratories Stock News firmly among the Stocks in News and Top Gainers Today on a price-rise basis alone.

Dr. Reddy's Laboratories Ltd. (DRREDDY) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 95,591.76 crore
P/E Ratio	30.36x
P/B Ratio	2.56x
ROE	11.69%
ROCE	13.75%
EPS	Rs 38.6
Book Value Per Share	Rs 457.39
Dividend Yield	0.68%

Dr. Reddy's Laboratories Ltd. (DRREDDY) fundamental metrics show P/E 30.36x, P/B 2.56x, ROE 11.69%, ROCE 13.75%. These figures provide context only and are not a buy or sell signal.

Dr. Reddy's Laboratories Ltd. has a market capitalisation of Rs 95591.76 crore and falls in the Large Cap category, which gives readers a sense of company size before judging valuation. On valuation, P/E at 30.36x, P/B at 2.56x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 11.69% and ROCE of 13.75%, helping investors compare shareholder returns and capital efficiency. Additional supplied metrics include EPS of Rs 38.6, book value per share of Rs 457.39, dividend yield of 0.68%, adding context to earnings, balance-sheet value and historical payout. Against the supplied same industry benchmark, these figures can be compared with benchmark median P/E of 32.69x, median ROE of 11.78%, median ROCE of 13.65%. These numbers explain the fundamental backdrop without converting the article into a buy or sell view.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Industry	Pharmaceuticals & Drugs
Benchmark Scope	same industry
Company P/E Ratio	30.36x
Benchmark Median P/E	32.69x
Benchmark Average P/E	44.72x
Benchmark P/E Range	3.44x to 417.17x
Company P/B Ratio	2.56x
Benchmark Median P/B	3.1x
Company ROE	11.69%
Benchmark Median ROE	11.78%
Company ROCE	13.75%
Benchmark Median ROCE	13.65%
Company Market Capitalisation	Rs 95,591.76 crore
Benchmark Median Market Cap	Rs 741.38 crore

Dr. Reddy's Laboratories Ltd. (DRREDDY) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.

Dr. Reddy's Laboratories Ltd. (DRREDDY) has a P/E ratio of 30.36x, which is below the benchmark median of 32.69x, a difference of -7.13%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.

Dr. Reddy's Laboratories Ltd. (DRREDDY) has a ROE of 11.69%, which is below the benchmark median of 11.78%, a difference of -0.76%. Dr. Reddy's Laboratories Ltd. (DRREDDY) has a ROCE of 13.75%, which is above the benchmark median of 13.65%, a difference of +0.73%.

Track stocks leading today through the Univest top gainers screener. The peer table below provides the company-level comparison.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Sun Pharmaceutical Industries Ltd.	SUNPHARMA	4,44,716.74	37.01	5.18	14.85	19.11
Divi's Laboratories Ltd.	DIVISLAB	2,44,223.13	84.83	14.05	16.19	21.51
Torrent Pharmaceuticals Ltd.	TORNTPHARM	1,83,453.32	85.3	20.73	26.76	19.27
Zydus Lifesciences Ltd.	ZYDUSLIFE	1,10,224.17	25.14	4.21	19.69	21.39
Cipla Ltd.	CIPLA	1,09,848.55	32.89	3.15	11.83	16

Dr. Reddy's Laboratories Ltd. (DRREDDY) has a P/E ratio of 30.36x compared with the displayed peer median of 37.01x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 11.69% compares with a peer median of 16.19% across the companies shown in the table. ROCE stood at 13.75% versus the displayed peer median of 19.27%, providing a capital-efficiency comparison. Dr. Reddy's Laboratories Ltd. (DRREDDY) has a market capitalisation of Rs 95,591.76 crore. Among the 5 peers shown, 5 have a larger market capitalisation.

Why Investors Are Watching Dr. Reddy's Laboratories

• Dr. Reddy's Laboratories Share Price rose 2.73% today to Rs 1,204, with a gain of Rs 31.95 from the previous close.
• The stock finished close to its intraday high of Rs 1,204.25 and well above the day low of Rs 1,172.05.
• Turnover stood at Rs 4.12 crore, giving a factual traded-value measure for the session.
• P/E of 30.36 and P/B of 2.56 sit below the same-industry median benchmarks of 32.69 and 3.10.
• ROE of 11.69%, ROCE of 13.75% and EPS of Rs 38.6 provide a measurable fundamentals backdrop for Dr. Reddy's Laboratories Stock News.

About Dr. Reddy's Laboratories

Dr. Reddy's Laboratories Ltd. operates in the Healthcare sector and the Pharmaceuticals & Drugs industry. The company is known for its pharmaceutical business in a listed market context where price, valuation and profitability are often reviewed together. Based on the supplied financial data, the company has a market capitalisation of Rs 95,591.76 crore, EPS of Rs 38.6, book value of Rs 457.39 and dividend yield of 0.68%.

For readers following Dr. Reddy's Laboratories Stock Performance, the business context matters because pharmaceuticals are typically assessed through earnings quality, return ratios and relative valuation as much as by day-to-day share price movement. That is why Dr. Reddy's Laboratories Share Price, Dr. Reddy's Laboratories Stock News and Dr. Reddy's Laboratories Fundamental Analysis are often read together on Univest. The company sits within a broad, competitive listed universe, and its latest share price rise adds a new data point for market watchers evaluating the stock alongside its sector peers.

Track Dr. Reddy's Laboratories Share Price on Univest

Use Dr. Reddy's Laboratories Ltd. (DRREDDY) live share-price page, Univest top gainers screener, Univest market blogs to review live stock data, top-gainers lists and related market analysis.

Users can track Dr. Reddy's Laboratories Share Price Live on Univest for the latest share price update, company news, fundamental ratios, shareholding pattern, market cap, and listed sector context. Univest also brings together company overview pages, peer comparison, valuation metrics, and key market insights so that Dr. Reddy's Laboratories Share Price Today can be viewed alongside broader stock analysis. For readers looking at Dr. Reddy's Laboratories NSE and Dr. Reddy's Laboratories BSE references, Univest keeps the stock detail view central and easy to follow.

Frequently Asked Questions

Why did Dr. Reddy's Laboratories Share Price rise today?

Ans. The data confirms a 2.73% rise to Rs 1,204, but it does not establish a company-specific catalyst. The move is best read as a verified price event alongside turnover, valuation and sector context.

What is Dr. Reddy's Laboratories Share Price Today?

Ans. Dr. Reddy's Laboratories Share Price Today is Rs 1,204. It advanced Rs 31.95, or 2.73%, from the previous close of Rs 1,172.05, and the stock closed near its intraday high.

What is the market capitalisation of Dr. Reddy's Laboratories?

Ans. The company’s market capitalisation is Rs 95,591.76 crore. That places Dr. Reddy's Laboratories above the same-industry median and average market-cap reference points in the supplied healthcare benchmark universe. The company operates in the Healthcare sector.

How does Dr. Reddy's Laboratories look on valuation?

Ans. Dr. Reddy's Laboratories has a P/E of 30.36 and a P/B of 2.56. Both are below the same-industry benchmark medians, which gives the stock a lower valuation profile than many listed peers.

What do the profitability ratios show for Dr. Reddy's Laboratories?

Ans. ROE is 11.69% and ROCE is 13.75%. ROE is close to the industry median, while ROCE is slightly above it, suggesting the company sits near the centre of the benchmark range.

What do EPS, book value and dividend yield mean here?

Ans. EPS is Rs 38.6, book value is Rs 457.39 per share and dividend yield is 0.68%. These three figures help frame earnings, accounting net worth and payout context for Dr. Reddy's Laboratories Share Price.

How does Dr. Reddy's Laboratories compare with peers?

Ans. Compared with listed peers in Healthcare, Dr. Reddy's Laboratories has a lower P/B than the supplied peer set and a P/E below several premium-valued names. Its ROE and ROCE sit in a moderate range.

Should investors track Dr. Reddy's Laboratories Share Price on Univest?

Ans. Univest lets users follow Dr. Reddy's Laboratories Share Price Today, market cap, fundamental ratios, shareholding pattern and sector context in one place. That makes it easier to review fresh data without mixing it with speculation.